Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Cyclophosphamide 13Methotrexate 12Cytarabine 11Dexamethasone 10Vincristine 9Etoposide 7Radiotherapy 6Mercaptopurine 6Daunorubicin 6Asparaginase 6pegaspargase 5blinatumomab 5Dasatinib 5Prednisone 4Methylprednisolone 4Filgrastim 4Doxorubicin 4ruxolitinib 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Busulfan 3Antilymphocyte Serum 3venetoclax 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2calaspargase pegol 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × deltacortene × Clear all
NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2/3 Completed
63 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡